Since its discovery in the mid-80's, evidence has accumulated to suggest that the cardiac natriuretic peptides (NPs) play an important role in salt and water homeostasis and blood pressure (BP) control, 1,2 and with the discovery by Newton-Cheh and colleagues in 2009 that genetically determined circulating NP concentrations are associated with BP levels and risk of hypertension, the pivotal role of the cardiac NPs in the regulation of BP and in the pathogenesis of hypertension was established. 3 Newton-Cheh and colleagues genotyped single-nucleotide polymorphisms (SNPs) at the NPPA (NP precursor A) and the NPPB (NP precursor B) loci and found that genotypes in three SNPs (rs5068, rs198358, and rs632793) were significantly associated with circulating NP levels, and that genotypes in two of these SNPs (rs5068 and rs198358) were also significantly associated with BP levels and risk of hypertension. 3 Their BP results were based on office BP measurements (OBPMs), 3 and although the associations were highly significant, the differences in BP levels among the genotypes of rs5068 and rs198358 only amounted to 0.9-1.5 mm Hg for systolic BP and 0.3-0.8 mm Hg for diastolic BP. 3 Compared with other quantitative traits, such as height and weight, BP shows great liability depending on state of mind and level of physical activity. Consequently, the "true" high BP phenotype is difficult to establish. From a clinical perspective, it has been shown repetitively that determining BP levels with 24-h ambulatory BP measurements (ABPMs) provides a better estimate of cardiovascular disease (CVD) risk than determining BP levels in the nurse's or the doctor's office. 4 Therefore, 24-h ABPMs are now regarded as the gold standard for the assessment of the total BP burden on the arterial wall, 5 and the 
Background
In a large collaborative study (n > 50,000), common variants in the natriuretic peptide (NP) genes were found to be associated with circulating NP levels and also with blood pressure (BP) levels based on office BP measurements (OBPMs). It is unknown if determining an individual's BP by 24-h ambulatory BP measurements (ABPMs) will influence the effect of NP gene variations on BP levels.
Methods
We used rs632793 at the NPPB (NP precursor B) locus to investigate the relationship between genetically determined serum N-terminal pro-brain NP (Nt-proBNP) concentrations and BP levels determined by both 24-h ABPMs and OBPMs in a population consisting of 1,397 generally healthy individuals taking no BP-lowering drugs. results rs632793 was significantly correlated with serum Nt-proBNP levels (r = 0.10, P = 0.0003), and participants with the A:A genotype had lower serum Nt-proBNP levels than participants with the G:G genotype (geometric mean (95% confidence interval (cI)): 34.8 (31.5-38.4) pg/ml vs. 48.1 (41.9-55.3) pg/ml, P = 0.0002), but higher 24-h ambulatory BP levels (mean difference (95% cI): 2.0 (0.1-4.1) mm Hg, P = 0.043, for systolic BP and 1.7 (0.4-3.1) mm Hg, P = 0.011, for diastolic BP). Office BP decreased across the genotypes from A:A to G:G, but the differences did not reach statistical significance (P ≥ 0.12).
original contributions Natriuretic Peptides and Blood Pressure gold standard to make the best diagnosis of hypertension. 6 So far, no studies have investigated if a more accurate determination of an individual's "true" BP by 24-h ABPMs will affect the genetic influence of SNPs at the NPPA and the NPPB loci on BP levels, although this issue is relevant as Fava and colleagues reported that ABP, in particular at night, seemed better than OBP to capture the heritable part of BP variation. 7 As we previously had measured circulating N-terminal pro-brain NP (NT-proBNP) concentrations in a large population-based sample in which BP had been measured both in the office and by 24-h ABPMs, 8, 9 we initiated this study: using rs632793 in the NPPB locus as a genetic instrument, we wanted to test the hypothesis that the genetic influence on BP levels would be easier to detect by means of 24-h ABPMs compared with OBPMs.
Study population. In 1982-1984, a random sample of 4,581 Danes, all of European ancestry, from Copenhagen County was invited to participate in the Danish Centre of the MONItoring of trends and determinants in CArdiovascular disease (MONICA) health survey. 10 Participants were selected to represent equal numbers of women and men aged 30, 40, 50, and 60 years. Eventually, 3,785 (83%) participated. In 1993-1994, all previously invited subjects for the first examination were re-invited to be re-examined. Since the first examination, 428 subjects had died and 23 had moved or could not be reached. Of the remaining 4,130 subjects, 2,656 (64%) were willing to participate. All subjects completed a questionnaire about current and previous diseases, intake of medication, and lifestyle risk factors. The study was conducted in agreement with the Second Helsinki Declaration, and the Danish MONICA study was approved by the local ethics committee system in Denmark. Written informed consent was obtained from all participants. The present investigation of genetic determinants of cardiovascular phenotypes was approved as a separate protocol (KA-04130).
As the focus of this investigation primarily was on ABP, and as we wanted to avoid the influence of CVD and cardiovascular drugs on BP and NP levels, 11 we first selected those who had a 24-h ABPM that complied with international recommendations: at least 14 readings of systolic and diastolic BP during the day and at least 7 readings of systolic and diastolic BP during the night. 12 Overall, 1,834 participants fulfilled this criterion. From this group, we excluded 129 subjects owing to a diagnosis of myocardial infarction or stroke or use of digoxin or nitrates, 236 subjects owing to use of other cardiovascular drugs, including BP-lowering drugs, 29 subjects owing to a diagnosis of diabetes, and 43 subjects owing to lack of material for genotyping, leaving 1,397 generally healthy women and men to be studied in the primary analyses. Thus, our primary study population was not a general population-based sample but a selected sample of generally healthy individuals.
Genotyping. Genotyping of rs632793, was done by KBioscience, Manchester, UK (http://www.kbioscience.co.uk). The in-house assay KASPer or the TaqMan systems (Applied Biosystems, Foster City, CA) were used. The assays were validated prior to use and by 5% duplicates in the population. rs632793 was in Hardy-Weinberg equilibrium (using the probability test in Genepop v.4.0.10 on the web: http://genepop.curtin.edu.au/).
Laboratory evaluation. Fasting concentrations of lipids were measured using enzymatic colorimetric methods (Roche, Mannheim, Germany). Fasting serum insulin was determined by an enzyme-linked two-site immunoassay specific for intact insulin and without cross-reactivity for proinsulin. 13 Fasting plasma glucose was analyzed using a hexokinase reagent kit. 13 C-reactive protein (CRP) levels were measured using a particle-enhanced immunoturbidimetry CRP assay (Roche/ Hitachi; Roche Diagnostics, Basel, Switzerland) with a range of 0.1-20 mg/l and a detection limit of 0.03 mg/l. 13 Serum NT-proBNP concentrations were determined using Elecsys proBNP sandwich immunoassay on an Elecsys 2010 (Roche Diagnostics). 11 The analytical range extended from 5.1 to 34,9 pg/ml. Between-assay coefficients of variation in low and high ranges of NT-proBNP are reported to be 4.8 and 2.7%, respectively.
Clinical evaluation. A physical examination was performed by trained staff and included anthropometric measurements (weight, height, waist, and hip circumference) and recordings of OBP and an electrocardiogram. OBP was measured in the sitting position after 5 min of rest using a random zero mercury sphygmomanometer. The mean of 2 measurements was reported. Information about lifestyle risk factors (smoking habits, alcohol consumption, and level of physical activity) was obtained from the questionnaire. Participants, who were sedentary or only slightly active <4 h/week, were defined as having a low level of physical activity.
The ABPM was initiated immediately after recording of the OBP using a validated Takeda TM-2421 (A&D, Tokyo, Japan) device. 14 Oscillometric recordings were used in this study. 9 BP recordings were made every 15 min between 7:00 AM and 11:00 PM, and every 30 min between 11:00 PM and 7:00 AM. Means of ABP and heart rate were computed with weights according to the time interval between successive readings. 9 The discrimination between daytime and nighttime was based on a diary, and when this information was inadequate (n = 73), we defined daytime as the interval between 6:00 AM and 12:00 AM and nighttime from 12:00 AM to 6:00 AM. Nondipping was defined as a decrease in systolic and diastolic BP of <10% from day to night, and BP variability was assessed using the s.d. over 24 h weighted for the time interval between consecutive readings. 15, 16 BP values were determined without detectable errors in 99% of the measurements. 17 Echocardiography was performed using M-mode and twodimensional echocardiograms and read by one experienced physician blinded to all other information. Left ventricular internal dimension and wall thickness were measured at end-diastole and end-systole following American Society of Echocardiography recommendations, 18 and endocardial original contributions Natriuretic Peptides and Blood Pressure ejection fraction was calculated. End-diastolic left ventricular dimensions were used to calculate left ventricular mass, which was corrected for body size by dividing with body surface area.
Definition of clinical conditions. To be used in our sensitivity analyses, we defined office hypertension as systolic OBP ≥140 mm Hg and/or diastolic OBP ≥90 mm Hg or use of BP-lowering drugs. With respect to cut off points for ambulatory hypertension, we were inspired by the criteria proposed by the International Database on Ambulatory BP monitoring in relation to Cardiovascular Outcomes (IDACO) investigators: 4 mean 24-h systolic ABP ≥130 mm Hg and/or mean 24-h diastolic ABP ≥80 mm Hg, or use of BP-lowering drugs, if the latter criterion was relevant, as in our sensitivity analyses. We defined diabetes, for identifying participants not admitted in the primary study population, as self-reported diabetes, hospitalisations with discharge diagnoses including diabetes or a fasting plasma glucose level ≥126 mg/dl, or use of antidiabetic drugs.
Statistical analyses. All analyses were performed with the Statistical Analysis System (SAS), version 9.1 (SAS Institute, Cary, NC) We present data as means ± s.d. or 95% confidence interval (CI) for normally distributed variables, as medians (interquartile range) for skewed distributed variables, and as proportions in percent for categorical variables. We tested for differences between groups using parametric or nonparametric one-way analysis of variance or χ 2 tests. In some cases, we log-transformed variables with skewed distributions to fulfill model assumptions for using parametric oneway analysis of variance, and in these cases we present data as geometric means. In sensitivity analyses, we used the fixed Cui/Harrap 10/5 mm Hg adjustment method to correct for use of antihypertensive medicine in our quantitative trait analyses. 19 Relationships between variables of interest were further explored using Spearman's rank correlation analysis. We used logistic regression analysis to explore the relationship between genotypes and a diagnosis of hypertension, and we used proportional odds models to determine which of the BPs of interest would be the strongest predictors of the genetic variance of rs632793. To test whether or not the associations were statistically significant different with the genotypes between the BPs of interest, we used the contrast statement in SAS (as an example "H0: diastolic OBP = diastolic ABP").
All statistical tests were two-sided and significance was concluded for values of nominal P < 0.05. results rs632793 displayed a high prevalence (~18%) of homozygocity for the minor allele "G", and rs632793 was significantly correlated with serum Nt-proBNP levels (r = 0.10, P = 0.0003).
General characteristics of the genotypes of rs632793 are summarized in Table 1 . Serum Nt-proBNP was the only variable that varied significantly across the genotypes, and participants with the A:A genotype had lower serum Nt-proBNP levels than participants with the G:G genotype (P = 0.0017). In Table 1 , we present serum Nt-proBNP as median (interquartile range).
The corresponding geometric means (95% CI) for serum Nt-proBNP levels were 34.8 (31.5-38.4) pg/ml for the A:A genotype, 41.9 (38.6-45.5) pg/ml for the G:A genotype, and 48.1 (41.9-55.3) pg/ml for the G:G genotype with significant differences found between the A:A and G:G genotypes (P = 0.0002) and between the A:A and G:A genotypes (P = 0.0045). Of the BP-related variables, participants with A:A genotype tended to have a higher left ventricular mass index, but the difference did not reach statistical significance in nonparametric one-way analysis of variance (P ≥ 0.12). However, calculating geometric means (95% CI) for left ventricular mass index showed that subjects with the A:A genotype had a higher left ventricular mass index than subjects with the G:G genotype (83.8 (81.6-94.7) g/m 2 vs. 79.3 (76.5-82.3) g/m 2 , P = 0.018), although this difference was no longer significant after adjustment was made for 24-h systolic and diastolic ABPs (P ≥ 0.090).
BP characteristics of the genotypes of rs632793 are summarized in Table 2 . Across the genotypes from A:A to G:G, there were steady decreases in mean 24-h systolic and diastolic ABP, and the mean differences (95% CI) between participants with the A:A genotype and participants with the G:G genotype were 2.0 (0.1-4.1) mm Hg, P = 0.043, for systolic BP and 1.7 (0.4-3.1) mm Hg, P = 0.011, for diastolic BP. The corresponding mean differences for the night BPs were 2.6 (0.4-4.8) mm Hg, P = 0.018, for systolic BP and 1.9 (0.4-3.3) mm Hg, P = 0.010, for diastolic BP. Of note, the mean difference (95% CI) between participants with the A:A genotype and participants with the G:G genotype only amounted to 0.9 (-0.7 to 2.4) mm Hg, P = 0.28, for diastolic OBP, and in a proportional odds model, including both mean 24-h diastolic ABP and diastolic OBP, only mean 24-h diastolic ABP was significantly associated with the genetic variance of rs632793 (P = 0.019), and the contrast statement analysis showed that the association between mean 24-h diastolic ABP and the genotypes of rs632793 was significantly different from the association found between the genotypes of rs632793 and diastolic OBP (P = 0.027). In no other BP comparisons, the BPs of interest were found to contribute significantly to genetic variance. Of note, additional adjustment for age and sex produced basically identical results (Table 3) . Furthermore, the prevalence of ambulatory hypertension was 36.8% among participants with the A:A genotype, 33.8% among participants with the G:A genotype, and 28.2% among participants with the G:G genotype, and participants with the A:A genotype had a higher risk of ambulatory hypertension (odds ratio (95% CI): 1.49 (1.06-2.08), P = 0.036), compared with participants with the G:G genotype. Additional adjustment for age and sex produced basically an identical result (odds ratio (95% CI): 1.52 (1.08-2.15), P = 0.031). Finally, we found no interactions between the genotypes of rs632793 and sex and age on ABP levels (P ≥ 0.27), as we found no significant differences among the three genotypes of rs632793 with respect to BP variability or BP dipping status (P ≥ 0.11).
sensitivity analyses
In the whole study population (n = 2,416) (excluding only subjects with overt CVD), rs632793 was also significantly original contributions Natriuretic Peptides and Blood Pressure correlated with serum Nt-proBNP levels (r = 0.086, P < 0.0001), and participants with the A:A genotype had lower serum Nt-proBNP levels (median (interquartile range): 43.1 (17.3-83.7) pg/ml vs. 52.3 (26.7-104.1) pg/ml, P = 0.0003) than participants with the G:G genotype. In the whole study population, there were also no differences in age (P = 0.28) and sex distribution (P = 0.32) among the genotypes of rs632793, and participants with the A:A genotype had a higher risk of office hypertension compared with participants with the G:G genotype (odds ratio (95% CI): 1.32 (1.04-1.69), P = 0.013). Table 4 summarizes OBP characteristics of the genotypes of rs632793 in the whole study population. Although there were decreases in BPs across the genotypes of rs632793 from A:A to G:G, the differences did not reach statistical significance. Table 4 also shows the 24-h ABP characteristics of the genotypes of rs632793 in all participants with a qualifying 24-h ABPM (n = 1,648). Again there were gradual decreases in BP across the genotypes of rs632793 from A:A to G:G, and the differences reached statistical significance for diastolic BP.
discussion
The principal finding was that 24-h ABPM was a better method than OBPM for the identification of significant differences in BP levels related to the genetic influence of rs632793 on BP levels. Another important finding was that the A:A genotype of rs632793 was associated with lower circulating NP levels and higher 24-h BP levels and higher risk of hypertension. Thus, we were able to replicate the pioneering work of Newton-Cheh and colleagues that showed that common genetic variants at the NPPA-NPPB locus found to be associated with circulating NP concentrations contribute to interindividual variation in BP levels and risk of hypertension, 3 although the SNPs with significant associations with BP levels and hypertension were not the same in the two studies. In fact, this study appears to be the first to report that rs632693 at the NPPB locus contributes to interindividual variation in BP levels and risk of hypertension.
This study used the natural experiment of the random Mendelian assortment of alleles to show that geneticallydetermined alterations in NP concentrations are associated original contributions
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with changes in BP levels and risk of hypertension. 20 It was reassuring that the only variable that varied significantly across the genotypes of rs632793 was Nt-proBNP (Table 1) . So, the Mendelian randomization process was satisfactory with respect to rs632793 in our study population. The only other variable that tended to be different in subjects with the A:A genotype was left ventricular mass index, a variable closely related to BP levels. Nevertheless, the higher left ventricular mass index found in subjects with the A:A genotype makes sense as the higher ABP levels found in participants with the A:A genotype would be expected to cause some degree of left ventricular hypertrophy. However, in the context of left ventricular hypertrophy it is also worthy of note that several studies have in fact reported direct antihypertrophic roles of the NPs, such that the lower the NP levels the higher the cardiac mass. 21 Nevertheless, in this study participants with the A:A genotype did not have significantly higher left ventricular mass after adjustment was made for 24-h ABP levels. We found significant differences in ABP levels across the genotypes of rs632793 up to 2.6 mm Hg for systolic ABP and 1.9 mm Hg for diastolic ABP. The corresponding differences reported in the work of Newton-Cheh and colleagues amounted to 0.9-1.5 mm Hg for systolic OBP and 0.3-0.8 mm Hg for diastolic OBP. 3 With respect to risk of hypertension, we found an ~50% increased risk for ambulatory hypertension for participants with the alleles associated with lower Nt-proBNP concentrations. The corresponding increases in risk reported in the work of Newton-Cheh and colleagues amounted to 10-15%. 3 We speculate that the more accurate determination of the participants' "true" BP status by 24-h ABPM and our more homogenous study population enabled us to detect a more pronounced genetic influence on BP levels. It is a limitation that we used the biologically inactive substance NT-proBNP as a measure of NP activity. 22 Nevertheless, as r 2 values exceeding 0.4 between circulating levels of NT-proBNP and BNP have been reported, 23 and as the G:G genotype of rs632793 was associated with higher circulating BNP levels in the study by Newton-Cheh and colleagues, 3 it seems reasonable to assume that higher NT-proBNP levels translated into higher circulating levels of biologically active BNP in our study population.
Perspectives
This study provides further evidence that 24-h ABPM is a better method than OBPM for the identification of significant differences in BP levels related to genetic variance. 7 In addition, this study provides further evidence that the NPs play an important role in the regulation of BP and in the pathogenesis of hypertension.
